CA2974925C - Methods of preventing secondary infections - Google Patents

Methods of preventing secondary infections Download PDF

Info

Publication number
CA2974925C
CA2974925C CA2974925A CA2974925A CA2974925C CA 2974925 C CA2974925 C CA 2974925C CA 2974925 A CA2974925 A CA 2974925A CA 2974925 A CA2974925 A CA 2974925A CA 2974925 C CA2974925 C CA 2974925C
Authority
CA
Canada
Prior art keywords
infection
mmp
influenza
mouse
ecm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2974925A
Other languages
English (en)
French (fr)
Other versions
CA2974925A1 (en
Inventor
Irit Sagi
Dalit TALMI-FRANK
Inna SOLOMONOV
Ido Amit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CA2974925A1 publication Critical patent/CA2974925A1/en
Application granted granted Critical
Publication of CA2974925C publication Critical patent/CA2974925C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA2974925A 2015-02-09 2016-02-09 Methods of preventing secondary infections Active CA2974925C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113551P 2015-02-09 2015-02-09
US62/113,551 2015-02-09
PCT/IL2016/050156 WO2016128975A1 (en) 2015-02-09 2016-02-09 Methods of preventing secondary infections

Publications (2)

Publication Number Publication Date
CA2974925A1 CA2974925A1 (en) 2016-08-18
CA2974925C true CA2974925C (en) 2022-03-22

Family

ID=56615084

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974925A Active CA2974925C (en) 2015-02-09 2016-02-09 Methods of preventing secondary infections

Country Status (7)

Country Link
US (2) US10610588B2 (enExample)
EP (1) EP3256135A4 (enExample)
JP (2) JP6783777B2 (enExample)
BR (1) BR112017017115A2 (enExample)
CA (1) CA2974925C (enExample)
HK (1) HK1244667A1 (enExample)
WO (1) WO2016128975A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256135A4 (en) 2015-02-09 2018-06-27 Yeda Research and Development Co. Ltd. Methods of preventing secondary infections
USD841023S1 (en) * 2017-08-24 2019-02-19 Domo, Inc. Display screen or portion thereof with a graphical user interface
WO2021257894A1 (en) * 2020-06-19 2021-12-23 Board Of Regents, The University Of Texas System Anti-bst2 antibodies targeting bst2 long isoform

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
EP1624866A2 (en) 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
US7910620B2 (en) * 2005-04-22 2011-03-22 Broadhurst Iii Jack J Uses of neuraminidase inhibitors in infectious diseases
WO2015031654A2 (en) * 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
EP3256135A4 (en) 2015-02-09 2018-06-27 Yeda Research and Development Co. Ltd. Methods of preventing secondary infections

Also Published As

Publication number Publication date
EP3256135A4 (en) 2018-06-27
JP2018507847A (ja) 2018-03-22
US20200261577A1 (en) 2020-08-20
US20180028650A1 (en) 2018-02-01
US11400156B2 (en) 2022-08-02
JP2021020936A (ja) 2021-02-18
HK1244667A1 (zh) 2018-08-17
JP6783777B2 (ja) 2020-11-11
CA2974925A1 (en) 2016-08-18
JP7109515B2 (ja) 2022-07-29
WO2016128975A1 (en) 2016-08-18
US10610588B2 (en) 2020-04-07
BR112017017115A2 (pt) 2018-04-03
EP3256135A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
US20250082685A1 (en) Methods for attenuating viral infection and for treating lung injury
CA2873808C (en) Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
CN102791734B (zh) 源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体
US11400156B2 (en) Methods of preventing secondary infections
US20220296645A1 (en) Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo
TWI377212B (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2020247675A1 (en) Methods for attenuating viral infection and for treating lung injury
US12491385B2 (en) Targeting SARS-CoV-2 viral-immune interaction for COVID-19 therapy
EP3501551B1 (en) Therapeutic compositions and methods involving mrna transfection
WO2016079321A1 (en) Antagonists of setdb2 for use in the therapy of infectious diseases
Wu et al. Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes
CN120789263A (zh) Ulixertinib在治疗新型冠状病毒引起的肺组织炎症中的应用
JP2016520570A (ja) Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト
ES2766950A1 (es) ARHGEF6 como diana farmacéutica para trastornos neurológicos
US20220002400A1 (en) Methods of Treating Influenza A Virus Infections
WO2020260281A1 (en) Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection
WO2021007329A2 (en) Treatment of pulmonary fibrosis using inhibitors of neu1 sialidase
Sharma et al. The pharmacokinetics, bio-distribution and therapeutic efficacy of a trimeric nanobody against SARS-CoV-2 in the Syrian golden hamster COVID-19 model
US20240337666A1 (en) Compositions and treatments for coronavirus infections
McMahon The role of ADAMTS enzymes in influenza virus immunity
Stumpff II Pleural and Lung Macrophage Responses to Influenza A Virus Infection
CN118829437A (zh) 利用靶向TGFβ1和COX2的siRNA治疗2019-nCoV的方法
Zipfel et al. ICW–2021 Virtual Workshop of the International Complement Society (ICS)
WO2024015744A1 (en) Compositions and methods for treatment of virus-induced airway fibrosis
hoon Lee The picture theory of eight pathways of COVID-19 in the real world

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210127

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250811

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251112